With the exciting news that Novartis has received US FDA approval for Pluvicto for previously-treated patients with PSMA-positive metastatic castration-resistant prostate cancer, the TRP space is continuing to go from strength to strength.

This is why the upcoming 2nd Annual Targeted Radiopharmaceuticals Summit US program is even more comprehensive than ever, bringing you a tracked agenda covering the whole TRP landscape from discovery, translation, to clinical, late stage progress and challenges – a unique opportunity for your entire team to learn and network.

Join us to:

• Explore the novel target selection to re-route targeted radiopharmaceuticals from a niche-label therapeutic
• Navigate the regulation and reimbursement challenges to improve the accessibility of targeted radiopharmaceuticals
• Review theragnostic in the clinic to exploit the two-birds-one-stone potential of TRPs
• Discover the potential combination therapies with DDRi’s and IO to unlock synergy with other modalities
• Harness the platform technologies for optimized preclinical evaluation of drugs

All presented by top industry players such as Clarity Pharmaceuticals, SOFIE Biosciences, Lantheus, Fusion Pharmaceuticals, Rayze Bio, Telix Pharmaceuticals, OranoMed, Actinium Pharmaceuticals, and many more.

Download the brand-new event guide here to see a full overview 3-day content and speaker faculty: https://ter.li/8hn0z2